SCHEMBL1382907

SCHEMBL1382907

O=C(Nc1ccc2[nH]c(=O)sc2c1)C(=O)N1CCC(=Cc2ccc(Cl)cc2)CC1

nearest known ligand 0.54

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
GRIN1 Q05586 6/20 0.54
GRIN2B Q13224 6/20 0.54
GRIN2D O15399 5/20 0.54
GRIN3B O60391 5/20 0.54
GRIN2A Q12879 5/20 0.54
GRIN2C Q14957 5/20 0.54
GRIN3A Q8TCU5 5/20 0.54
SMN1; SMN2 Q16637 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
IDO1 P14902 1/20 0.39
P2RX3 P56373 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1384919 0.90 GRIN1 (0.65) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL1381735 0.90 GRIN1 (0.63) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL1383811 0.88 GRIN1 (0.60) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL1381738 0.85 GRIN2D (0.63) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL12508969 0.82 GRIN1 (0.57) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL1381192 0.82 GRIN2D (0.66) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL4576737 0.79 GRIN1 (0.82) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL1382197 0.75 GRIN2D (0.52) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL1386547 0.73 MAPT (0.57) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A
SCHEMBL1384443 0.72 GRIN2D (0.65) GRIN1GRIN2BGRIN2DGRIN3BGRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4814880-B2 2011-11-16 JP claimed
US-8008326-B2 4-benzyledene-piperidin derivatives RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2011-08-30 US claimed
US-20080312222-A1 4-Benzyledene-Piperidin Derivatives RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 2008-12-18 US claimed
JP-2008508247-A 2008-03-21 JP claimed
EP-1773810-B1 NEW 4-BENZYLIDENE-PIPERIDIN DERIVATIVES RICHTER GEDEON VEGYESZET (HU) 2008-02-27 EP claimed
EP-1773810-A1 NEW 4-BENZYLIDENE-PIPERIDIN DERIVATIVES RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) 2007-04-18 EP claimed
WO-2006010964-A1 NEW 4-BENZYLIDENE-PIPERIDIN DERIVATIVES Richter Gedeon Vegyészeti Gyár Rt. (HU) 2006-02-02 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312222-A1 4-Benzyledene-Piperidin Derivatives GRIN2C, GRIN2A, GRIN1 GRIN1 3/4885GRIN2B 4/4885GRIN2D 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.